BioSyent Inc.

BioSyent Inc.

May 26, 2016 08:00 ET

FeraMAX® Named #1 by Canadian Doctors and Pharmacists

TORONTO, ONTARIO--(Marketwired - May 26, 2016) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its FeraMAX® brand was recently named as the #1 recommended over-the-counter ("OTC") iron supplement brand in a national survey of Canadian physicians and pharmacists.

The survey was conducted by Rogers Connect™ Market Research group and the following publications within the Rogers Healthcare Group: Pharmacy Practice+, The Medical Post, and Profession Santé. This was the first time that the iron supplement category was included in this annual survey which was conducted between July and October 2015 with Canadian physicians and retail pharmacists. In total, over 3,141 surveys were completed. FeraMAX® was named by 31% of physicians surveyed and 33% of pharmacists surveyed as their most recommended iron supplement brand to Canadian patients.

FeraMAX® has established a unique position in the market by providing patients with an iron supplement with less gastrointestinal side effects and easy once a day dosing. FeraMAX® has continued to solidify its leadership position with market-focused line extensions. FeraMAX® Powder was launched for pediatric patients to help prevent iron deficiency and iron deficiency anemia. In addition, FeraMAX® Vegan Certified capsules were introduced this year, which provide the only certified iron therapy option for vegans, vegetarians, and patients with other dietary restrictions.

"We are very pleased with the #1 recommendation for FeraMAX® in the respected Rogers Healthcare Group survey" commented Mr. René Goehrum, President and CEO of BioSyent. "The innovative polysaccharide-iron complex of FeraMAX® has allowed BioSyent to differentiate itself from the competitors, and we are pleased that physicians and pharmacists have recognized the unique benefits FeraMAX® offers to patients, including improved safety, tolerability, and convenience."

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,026,087 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact Information